Orgenesis Provides Year End Business Update
April 15, 2024 17:07 ET
|
Orgenesis Inc.
Major transformation underway commencing with recent acquisitionreasserting full ownership and control over Octomera Secured a $2.3 million investment from a group including sophisticated healthcare...
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
April 10, 2024 12:00 ET
|
Orgenesis Inc.
ORMOND BEACH, Fla. and GERMANTOWN, Md., April 10, 2024 (GLOBE NEWSWIRE) -- Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (Nasdaq: ORGS), a global...
Lily AI’s Co-Founders Purva Gupta and Sowmiya Chocka Narayanan Make Inc.’s 2024 Female Founders List
April 09, 2024 09:15 ET
|
Lily AI
Lily AI’s Co-Founders Purva Gupta and Sowmiya Chocka Narayanan Make Inc.’s 2024 Female Founders List.
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference
March 18, 2024 08:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced...
Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes
March 13, 2024 08:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., March 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced...
Orgenesis Inc. Announces $2.3 Million Private Placement
March 04, 2024 08:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., March 04, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), announced today...
Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
February 29, 2024 08:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), today announced that...
With Extensive Two-Year Revenue Growth, ValueSelling Associates is Selected to Inc. Magazine’s List of the Pacific Region’s Fastest-Growing Private Companies
February 28, 2024 13:09 ET
|
ValueSelling Associates, Inc.
ValueSelling Associates has been selected to the Inc. 5000 Regionals Pacific list, showcasing the fastest-growing Pacific private companies.
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
January 31, 2024 09:15 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced it...
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 02, 2024 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients,...